Biogen Inc. said it plans to make a $100 million upfront payment to Samsung Bioepis to acquire the rights to commercialize biosimilar versions of Lucentis and Eylea, two blockbuster eye drugs. Samsung Bioepis is a joint venture founded in 2012 between the Cambridge, Mass.-based biotech and Samsung , the Korean conglomerate. Biogen said it will record a $65 million charge to its research and development expenses as a result of the transaction, which also includes potential additional milestone payments of up to $210 million. Biogen’s stock is down 2.9% for the year, while the S&P 500 is up 23%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- : European economic recovery was swift — but here’s why it’s likely to be brief - October 30, 2020
- : Even with $1.1 trillion firepower, this fund is battling rivals to get its hands on green-energy opportunities - October 30, 2020
- Cruise stocks surge after CDC announces ‘phased approach’ to cruises after no-sail order expires - October 30, 2020